AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19646174 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout intervention programme (details on dosage and duration not available)
Number of subjects: 18
Study 17825695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 100 mg in 100-mL saline
Number of subjects: 34
Study 17825695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100-mL saline)
Number of subjects: 34
Study 14975049 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (9 microgram/kg per hour)
Number of subjects: 152
Study 14975049 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1.5 microgram/kg per hour)
Number of subjects: 152
Study 14975049 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 152
Study 14975049 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 152
Study 14975049 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil and Fentanyl
Number of subjects: 152
Study 12642710 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women with endemic fluorosis
Number of subjects: 80
Study 12642710 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with endemic fluorosis
Number of subjects: 80
Study 12642710 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal controls
Number of subjects: 80
Study 10428346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Augmentin
Number of subjects: 171
Study 10428346 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 171
Study 7567006 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine in oxymetazoline
Number of subjects: 0
Study 7567006 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetracaine in oxymetazoline
Number of subjects: 0
Study 2406858 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid bismuth subsalicylate (BSS) 60 mL four times daily (4.2 g of BSS/d) for 3 weeks
Number of subjects: 234
Study 2406858 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS 2 tablets four times daily (2.1 g of BSS/d) for 3 weeks
Number of subjects: 234
Study 2406858 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS 1 tablet four times daily (1.05 g of BSS/d) for 3 weeks
Number of subjects: 234
Study 2406858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets taken four times daily) for 3 weeks
Number of subjects: 234
Study 2406858 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS (all dosages)
Number of subjects: 234
Study 2406858 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS-treated subjects with diarrhea
Number of subjects: 234
Study 7437276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 2.5 g
Number of subjects: 0
Study 7437276 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 0
Study 31536806 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE 0.625 mg/day) plus medroxyprogesterone acetate (MPA 2.5 mg/day)
Number of subjects: 27425
Study 31536806 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE 0.625 mg/day) alone
Number of subjects: 27425
Study 31536806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27425
Study 30739657 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe + simvastatin
Number of subjects: 18144
Study 30739657 — intervention group
Group type: COMPARATOR
Intervention: placebo + simvastatin
Number of subjects: 18144
Study 28891251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg q.d.
Number of subjects: 0
Study 28891251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg q.d.
Number of subjects: 0
Study 28891251 — intervention group
Group type: COMPARATOR
Intervention: Baricitinib (twice-daily regimen)
Number of subjects: 0
Study 26702941 — intervention group
Group type: EXPERIMENTAL
Intervention: Airwall film dressing (group A)
Number of subjects: 271
Study 26702941 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments (group B)
Number of subjects: 271
Study 24806137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (0.1 μg/mL)
Number of subjects: 10
Study 24806137 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.1 μg/mL)
Number of subjects: 10
Study 24806137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam and Meperidine (both at 0.1 μg/mL)
Number of subjects: 10
Study 24806137 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 10
Study 22628593 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flex PS TKR
Number of subjects: 24
Study 22628593 — intervention group
Group type: COMPARATOR
Intervention: Gender-specific high-flexion PS TKR
Number of subjects: 24
Study 19317814 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg of Ca(2+) orally, daily for 8 weeks
Number of subjects: 31
Study 19317814 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 31
Study 17804335 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ascorbate for 1 min
Number of subjects: 6
Study 17804335 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ascorbate for 3 min
Number of subjects: 6
Study 17804335 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ascorbate for 10 min
Number of subjects: 6
Study 17804335 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% ascorbate for 1 min
Number of subjects: 6
Study 17804335 — intervention group
Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 6
Study 17804335 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 6
Study 15710809 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 419
Study 15710809 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine eye drops
Number of subjects: 419
Study 15710809 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 419
Study 11741362 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 3697
Study 11741362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3697
Study 9836755 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation focused on impairment (theoretically driven)
Number of subjects: 184
Study 9836755 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation oriented on disability (pragmatic)
Number of subjects: 184
Study 9836755 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 184
Study 7916853 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally supported education
Number of subjects: 2000
Study 7916853 — intervention group
Group type: COMPARATOR
Intervention: Private instruction by parents or other private teachers
Number of subjects: 2000
Study 31347016 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHS curriculum
Number of subjects: 5218
Study 31347016 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 5218
Study 31119469 — intervention group
Group type: EXPERIMENTAL
Intervention: Signs of DSED in early childhood
Number of subjects: 136
Study 31119469 — intervention group
Group type: EXPERIMENTAL
Intervention: Diminished signs of DSED by age 12 years
Number of subjects: 136
Study 27997725 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient cream (Dexeryl®) containing glycerol 15%, liquid and soft paraffin 10%, and other ingredients, applied twice daily for 27 ± 2 days
Number of subjects: 57
Study 27997725 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (glycerol monostearate, stearic acid, polydimethylcyclosiloxane, silicone oil, macrogol 600, trolamine, propyl parahydroxybenzoate and purified water)
Number of subjects: 57
Study 27585792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cann‐CBD (8 mg THC)
Number of subjects: 37
Study 27585792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cann + CBD (8 mg THC + 10 mg CBD)
Number of subjects: 37
Study 27585792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 27585792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-dependent group
Number of subjects: 37
Study 27585792 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-dependent, drug-using)
Number of subjects: 37
Study 25158709 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections into the orbicularis oris muscle
Number of subjects: 60
Study 25158709 — intervention group
Group type: COMPARATOR
Intervention: Vehicle injections into the orbicularis oris muscle
Number of subjects: 60
Study 22178274 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-needle technique for TMJ arthrocentesis plus hyaluronic acid injections
Number of subjects: 80
Study 22178274 — intervention group
Group type: COMPARATOR
Intervention: Single-needle technique for TMJ arthrocentesis plus hyaluronic acid injections
Number of subjects: 80
Study 22178274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 80
Study 19728752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 0
Study 19728752 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 0
Study 16635050 — intervention group
Group type: EXPERIMENTAL
Intervention: Active analgesics
Number of subjects: 0
Study 16635050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15579788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose T3 (25 microg) with paroxetine 30 mg daily
Number of subjects: 113
Study 15579788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose T3 (25 microg twice daily) with paroxetine 30 mg daily
Number of subjects: 113
Study 15579788 — intervention group
Group type: COMPARATOR
Intervention: Placebo with paroxetine 30 mg daily
Number of subjects: 113
Study 11704586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IL-5 (2 microg)
Number of subjects: 9
Study 11704586 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled IL-5 (15 microg)
Number of subjects: 9
Study 9193050 — intervention group
Group type: EXPERIMENTAL
Intervention: Level discrimination task with varying levels of randomization
Number of subjects: 0
Study 9193050 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape discrimination task
Number of subjects: 0
Study 9193050 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectability of a level increment in a multitone complex
Number of subjects: 0
Study 12959313 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg day(‐1))
Number of subjects: 18
Study 12959313 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol with diclofenac
Number of subjects: 18
Study 12959313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg day(‐1))
Number of subjects: 18
Study 12959313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2825462 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.02 mg/kg
Number of subjects: 60
Study 2825462 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.03 mg/kg
Number of subjects: 60
Study 2825462 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.04 mg/kg
Number of subjects: 60
Study 2825462 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.05 mg/kg
Number of subjects: 60
Study 29792404 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE DES
Number of subjects: 170
Study 29792404 — intervention group
Group type: COMPARATOR
Intervention: SYNERGY DES
Number of subjects: 170
Study 29792404 — intervention group
Group type: EXPERIMENTAL
Intervention: Culotte stenting
Number of subjects: 170
Study 27599223 — intervention group
Group type: EXPERIMENTAL
Intervention: Full U.S.-THRIVE condition (direct and indirect PBS)
Number of subjects: 208
Study 27599223 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect-only U.S.-THRIVE condition
Number of subjects: 208
Study 27599223 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-only U.S.-THRIVE condition
Number of subjects: 208
Study 27599223 — intervention group
Group type: COMPARATOR
Intervention: Education/assessment control
Number of subjects: 208
Study 23765874 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care programme to prevent depression and anxiety
Number of subjects: 0
Study 23765874 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23765874 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care programme
Number of subjects: 0
Study 23139427 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisually cued training (3 times per week for 4 weeks)
Number of subjects: 21
Study 23139427 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 21
Study 20639294 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic interventions
Number of subjects: 41605
Study 18447946 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with a proton pump inhibitor
Number of subjects: 439
Study 15890044 — intervention group
Group type: EXPERIMENTAL
Intervention: LTI-SAGE intervention (maximum of 12 groups over 12 months)
Number of subjects: 69
Study 15890044 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 69
Study 12810925 — intervention group
Group type: EXPERIMENTAL
Intervention: CARD15/NOD2 mutations in RA patients
Number of subjects: 210
Study 12810925 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-RA)
Number of subjects: 210
Study 10505445 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatment
Number of subjects: 29
Study 10505445 — intervention group
Group type: COMPARATOR
Intervention: Reposition and splinting
Number of subjects: 29
Study 7847434 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP/SMX thrice weekly (3 times per week)
Number of subjects: 107
Study 7847434 — intervention group
Group type: COMPARATOR
Intervention: TMP/SMX daily (twice daily)
Number of subjects: 107
Study 7847434 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin with TMP/SMX
Number of subjects: 107
Study 7847434 — intervention group
Group type: COMPARATOR
Intervention: Non-leucovorin with TMP/SMX
Number of subjects: 107
Study 1826822 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose gestagen treatment
Number of subjects: 156
Study 1826822 — intervention group
Group type: COMPARATOR
Intervention: Abrasio alone
Number of subjects: 156
Study 1826822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of abrasio and high-dose gestagen treatment
Number of subjects: 156
Study 7010164 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine endoscopy
Number of subjects: 206
Study 7010164 — intervention group
Group type: COMPARATOR
Intervention: No routine endoscopy
Number of subjects: 206
Study 31171928 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone treatment for 14 days
Number of subjects: 90
Study 31016268 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio‐Economic‐Health Deprivation Index (SEHDI)
Number of subjects: 0
Study 31016268 — intervention group
Group type: EXPERIMENTAL
Intervention: Belonging to families with 3 or 4 members
Number of subjects: 0
Study 31016268 — intervention group
Group type: COMPARATOR
Intervention: General population in the Foggia municipality
Number of subjects: 0
Study 27458060 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical activity program (120 min/week for 24 weeks)
Number of subjects: 40
Study 27458060 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 40
Study 24163093 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraarticular infusion of 0.2% ropivacaine
Number of subjects: 94
Study 24163093 — intervention group
Group type: COMPARATOR
Intervention: Epidural plus femoral nerve block (FNB)
Number of subjects: 94
Study 23136289 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by lady health workers (LHWs) using oral antibiotics
Number of subjects: 0
Study 23136289 — intervention group
Group type: COMPARATOR
Intervention: Referred cases
Number of subjects: 0
Study 23136289 — intervention group
Group type: EXPERIMENTAL
Intervention: Community managed cases (excluding cost of antibiotics)
Number of subjects: 0
Study 23136289 — intervention group
Group type: COMPARATOR
Intervention: Referred cases (excluding cost of antibiotics)
Number of subjects: 0
Study 19800973 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled (CC) arm
Number of subjects: 0
Study 17210513 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculotherapy using magnetic pellets
Number of subjects: 60
Study 17210513 — intervention group
Group type: COMPARATOR
Intervention: Semen Vaccariae (control group)
Number of subjects: 60
Study 14739797 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ng/ml remifentanil
Number of subjects: 74
Study 14739797 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ng/ml remifentanil
Number of subjects: 74
Study 14739797 — intervention group
Group type: COMPARATOR
Intervention: No remifentanil infusion (control)
Number of subjects: 74
Study 11175678 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed 'Up & Go' test (TUG) during 'off' phase of levodopa (after 12 hours withdrawal)
Number of subjects: 24
Study 11175678 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed 'Up & Go' test (TUG) during 'on' phase of levodopa (1 hour after administration)
Number of subjects: 24
Study 11175678 — intervention group
Group type: COMPARATOR
Intervention: Timed 'Up & Go' test (TUG) for comparison subjects
Number of subjects: 24
Study 11175678 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of TUG scores between 'on' and 'off' phases of levodopa
Number of subjects: 24
Study 11175678 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TUG scores between subjects with PD and comparison subjects during 'on' phase
Number of subjects: 24
Study 9833003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg ethanol
Number of subjects: 10
Study 9833003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg ethanol
Number of subjects: 10
Study 9833003 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 10
Study 9833003 — intervention group
Group type: COMPARATOR
Intervention: 0 g/kg ethanol (control)
Number of subjects: 10
Study 7949539 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (FeDs, n = 12)
Number of subjects: 51
Study 7949539 — intervention group
Group type: COMPARATOR
Intervention: No iron supplementation (FeDns, n = 12)
Number of subjects: 51
Study 7949539 — intervention group
Group type: COMPARATOR
Intervention: Normal iron status (FeN, n = 27)
Number of subjects: 51
Study 7949539 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-deficient patients (FeD)
Number of subjects: 51
Study 7949539 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo production
Number of subjects: 51
Study 3357722 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise, diet therapy, and behavior change
Number of subjects: 36
Study 3357722 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy and behavior change
Number of subjects: 36
Study 3357722 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 29703187 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care intervention (CTC)
Number of subjects: 3500
Study 29703187 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention communities)
Number of subjects: 3500
Study 27106362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus riluzole (50 mg twice daily)
Number of subjects: 50
Study 27106362 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine plus placebo
Number of subjects: 50
Study 24753831 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Dilatational Tracheostomy (PDT)
Number of subjects: 60
Study 24753831 — intervention group
Group type: COMPARATOR
Intervention: Surgically Created Tracheostomy (SCT)
Number of subjects: 60
Study 22487370 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medicines (specifics not provided)
Number of subjects: 102
Study 22487370 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 consecutive new cases)
Number of subjects: 102
Study 20543758 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy with home reinforcement (OBVAT)
Number of subjects: 221
Study 20543758 — intervention group
Group type: COMPARATOR
Intervention: Home-based pencil push-ups (HBPP)
Number of subjects: 221
Study 20543758 — intervention group
Group type: COMPARATOR
Intervention: Home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+)
Number of subjects: 221
Study 20543758 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy with home reinforcement (OBPT)
Number of subjects: 221
Study 18284711 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (300 mg per day for 20 days)
Number of subjects: 18
Study 18284711 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg per day for 20 days)
Number of subjects: 18
Study 15218517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 25 mg triamcinolone acetonide
Number of subjects: 187
Study 15218517 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 187
Study 12220476 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 40
Study 12220476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study 12220476 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast vs Placebo
Number of subjects: 40
Study 12220476 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary LTE4 excretion
Number of subjects: 40
Study 10574416 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine treatment
Number of subjects: 14
Study 10574416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9180949 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alfa 2b 3 MU t.i.w. during 24 weeks (group I)
Number of subjects: 44
Study 9180949 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alfa 2b 3 MU t.i.w. during 48 weeks (group II)
Number of subjects: 44
Study 1767175 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxerutine (4 g/day)
Number of subjects: 26
Study 1767175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26